Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

J Hans DeVriesTimothy S BaileyAnuj BhargavaGregg GeretyJanusz GumprechtSimon R HellerWendy LaneCarol H Wysham Bernard ZinmanBritta A BakElise Hachmann-NielsenAthena Philis-Tsimikas

Published in: Diabetes, obesity & metabolism (2018)

Higher day-to-day fasting SMBG variability is associated with an increased risk of overall symptomatic, nocturnal symptomatic and severe hypoglycaemia. Degludec has significantly lower day-to-day fasting SMBG variability vs glargine U100.

Keyphrases

blood glucose
glycemic control
type diabetes
insulin resistance
blood pressure
obstructive sleep apnea
weight loss
early onset
metabolic syndrome
sleep quality
skeletal muscle
newly diagnosed